A proposition for a cancer treatment study using radioactive metal co-factor enzymes

Authors

  • Luyen Van Tran Former senior researcher, Vietnam Atomic Energy Commission (VAEC) Hanoi, Vietnam

DOI:

https://doi.org/10.15419/bmrat.v6i2.519

Keywords:

beta decay, electron capture, Enzyme, M*-enzyme, M-enzyme, metal cofactorenzyme, nuclear recoil, nuclear transformation, radioisotope-enzyme

Abstract

Cancer is a serious pathological condition of abnormal cells are gathered in tumors in the body's tissues or organs. Due to their accelerated metabolism, cancer cells require a great demand for energy, protein (cell structure substrates), and metabolic enzyme activity. If the body does not respond adequately to this demand, the metabolic processes of cancer cells will be hampered, and their growth will be limited or even stopped. It is possible to control the metabolic processes of the cancerous tumors by performing one or more of the following approaches: stopping the energy and cell structure substrate supply, inhibiting enzymic activity, and/or destroying cancer cells with external agents (such as radiation and/or chemicals). These approaches have been investigated either in single or combination modes, but so far the results obtained have not been on par with expectations. In this paper, we propose a method of cancer treatment which entails the use of a radioisotope instead of stable metal to break down the structure of metal co-factor enzyme and to deactivate its catalytic function. With a judicious choice of the metal radioisotope, this method is even able to perform all the above-mentioned approaches, and at the same time, giving a much better efficacy in cancer treatment.

 

Published

2019-02-17

Issue

Section

Opinion

How to Cite

A proposition for a cancer treatment study using radioactive metal co-factor enzymes. (2019). Biomedical Research and Therapy, 6(2), 2983-2985. https://doi.org/10.15419/bmrat.v6i2.519

Similar Articles

1-10 of 92

You may also start an advanced similarity search for this article.